Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA Seeks Pediatric Indication for Rifxima in Japan
June 21, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Daiichi Sankyo Chair Snares 402 Million Yen in FY2022: Securities Report
June 20, 2023
- Entyvio SC Now Available in Japan: Takeda
June 20, 2023
- Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
June 19, 2023
- Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
June 19, 2023
- As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
- PharmaEssentia Eyes Japan Sales of 50 Billion Yen in 2030
June 16, 2023
- Astellas Inks Protein Degrader Deal with Cullgen
June 16, 2023
- Opdivo Filed for Malignant Epithelial Tumors in Japan
June 16, 2023
- Azilva, Allermist Authorized Generics to Hit Japan Market on June 16
June 16, 2023
- Japan Regenerative Drug Market to Reach 72.3 Billion Yen in 2030: Fuji Keizai
June 16, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
- AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
- AbbVie Goes Solo in Humira Marketing and Promotion in Japan
June 14, 2023
- Argenx Makes World’s 1st Filing in Japan for Vyvgart’s ITP Use
June 14, 2023
- Keytruda Filed for Biliary Tract Cancer in Japan
June 14, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- US District Court Rejects Claim for Myrbetriq Patent Infringement, Astellas to Challenge Ruling
June 13, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…